The beneficial role of N-acetylcysteine as an adjunctive drug in treatment of COVID-19 patients in a tertiary care hospital in India: an observational study

Raja Bhattacharya, Maitry Mondal, Subhendu Bikash Naiya, Lamsaka Lyngdoh, Rishav Mukherjee, Prabhat K. Singh


Background: N-acetyl cysteine, a mucolytic agent, demonstrates free radical scavenging and anti-inflammatory properties, and prevents endothelial dysfunction by inhibition of NF-KB and formation of no adducts. This has a potential role to tackle cytokine storms, endothelial dysfunction and prothrombotic state observed in COVID-19 manifestations like ARDS and Multi organ dysfunction.

Methods: Institution based descriptive cross sectional study, 164 patients from laboratory confirmed RT PCR positive COVID-19 patients, in the study period from 27th May 2020 to 10th August 2020, were assessed, in medical college Kolkata, a dedicated COVID-19 care facility.

Results: It was observed that moderate-severe patients who received N-acetyl cysteine along with standard therapy had average hospital stay duration of 12 days, higher rate of discharge, average duration of oxygen therapy of 8 days, less number of deaths and reduced transfer to critical care facilities.

Conclusions: N-acetyl cysteine can be considered as an adjunctive therapy with standard protocol driven care, due to its beneficial anti-inflammatory and free radical scavenging properties.


COVID-19, N-acetyl cysteine, Free radical scavenger, Anti-inflammatory

Full Text:



Wu D, Wu T, Liu Q, Yang Z. The SARS-CoV-2 outbreak: What we know. Int J Infect Dis. 2020;94: 44-8.

Bikdeli B, Madhavan MV, Jimenez D, Church T, Dreyfus I, Driggin E, et al. COVID-19 and thrombotic or thromboembolic disease:implications for prevention, antithrombotic therapy, and follow-up. JACC. 2020;75(23):2950-73.

Ellul MA, Benjamin L, Singh B, Lant S, Michael BM, Easton A, et al. Neurological associations of COVID-19 Lancet Neurol. 2020;19(9):767-83.

Carsana L, Sonzogni A, Nasr A, Rossi R, Pellegrinelli A, Zerbi P, et al. Pulmonary post-mortem findings in a series of COVID-19 cases from northern Italy: a two-centre descriptive study. The Lancet Infectious disease. 2020;3043(20):1-6.

Zhou Y, Fu B, Zheng X, Wnag D, Zhao C, QI Y, et al. Pathogenic T cells and inflammatory monocytes incite inflammatory storms in severe COVID-19 patients. Natl Sci Rev. 2020;nwaa041.

Hurst GA, Shaw PB, LeMaistre CA. Laboratory and clinical evaluation of the mucolytic properties of acetyl-cysteine. Am Rev Respir Dis. 1967:96(5):962-70.

Aldini G, Altomare A, Baron G, Vistoli G, Carini M, Borsani L, et al. N-Acetylcysteine as an antioxidant and disulphide breaking agent: the reasons why. Free radical res. 2018;52(7):751-62.

Sagristá ML, García AE, Africa De Madariaga M, Mora M. Antioxidant and pro-oxidant effect of the thiolic com-pounds N-acetyl-L-cysteine and glutathione against free radical-induced lipid peroxidation. Free Radic Res. 2002;36(3):329-40.

Jang MK, Kim SH, Lee KY, Kim TB, Moon KA, Park CS, et al. The tyrosine phosphatase, SHP-1, is involved in bronchial mucin production during oxidative stress. Biochem Biophys Res Commun. 2010;393:137-43.

Goodman LS, Brunton LL, Chabner B, Knollmann BC. Goodman & Gilman's pharmacological basis of therapeutics. 12th ed. New York: McGraw-Hill; 2011:1057.

Hagiwara SI, Ishii Y, Kitamura S. Aerosolized administration of N-acetylcysteine attenuates lung fibrosis induced by bleomycin in mice. Am J Respir Crit Care Med. 2000;162:225-31.

Miller AC, Rivero A, Ziad S, Smith DJ, Elamin EM. Influence of nebulized unfractionated heparin and N-acetylcysteine in acute lung injury after smoke inhalation injury. J Burn Care Res. 2009;30:249-56.

Stamler JS, Slivika A. Biological chemistry of thiols in the vasculature and in vascular related disease. Nur Rev. 1996;54:1-30.

Andrews NP, Prasad A, Quyyumi A. N acetyl cysteine improves coronary and peripheral vascular function. J Am Coll Cardiol . 2001;37:117- 23.

Nishikawa Y, Kanki H, Ogawa S. Differential effects of N acetyl cysteine on nitroglycerin and nicorandil induced vasodilation in human coronary circulation. J Cardiovasc Pharmacol. 1998;32:21-8.

De Flora, Grassi C, Carati L. Attenuation of influenza- like symptomatology and improvement of cell mediated immunity with long term N acetyl cysteine treatment. Eur respirJ. 1997;10(7) :1535-41.

Mata M, Sarrion I, Armengot M, Carda C, Martinez I. Respiratory syncytial virus inhibits cilia genesis in differentiated normal human bronchial epithelial cells: effectiveness of N acetyl cysteine. PLOS ONE. 2012;7(10):e48037.

Soltan - Sharifi MS, Mojtahedzadeh M, Najafi A, Rouini MR, Khajavi MR, Moradi M, et al. Improvement by N acetyl cysteine of acute respiratory distress syndrome through increasing intracellular glutathione, and extracellular thiol molecules and antioxidant power: evidence for underlying toxicological mechanisms. Hum Exp Toxicol. 2007;26(9):697-703.

Prescott LF, Donovan JW, Jarvie DR, Proudfoot AT. The Disposition And Kinetics of Intravenous N acetylcysteine in patients with Paracetamol overdose. Eur J chin pharmacol. 1989;37:501-6.

Clinical management protocol: COVID-19 Government of India Ministry of Health and Family Welfare Directorate General of Health Services (EMR Division) Version 4. Available at: Accessed on 20 July 2020.

COVID-19 India as on: 10 August 2020, 08.00 IST (GMT + 5.30). Available at: https://www.mohfw. Accessed on 20 July 2020.

Jorge-Aarón RM, Rosa-Ester MP. N-acetylcysteine as a potential treatment for COVID-19. Future Microbiol. 2020;15:959-62.